|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"kang yk"
Showing items 21-30 of 30 (3 Page(s) Totally)
<< < 1 2 3
View [10|25|50] records per page
| 國家衛生研究院 |
2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
|
Kang, YK;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Boku, N;Chen, LT |
| 國家衛生研究院 |
2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
|
Boku, N;Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Chen, LT |
| 國家衛生研究院 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
|
Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT |
| 國家衛生研究院 |
2016-10 |
Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor
|
Koo, DH;Ryu, MH;Kim, KM;Yang, HK;Sawaki, A;Hirota, S;Zheng, J;Zhang, B;Tzen, CY;Yeh, CN;Nishida, T;Shen, L;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2016-08 |
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma
|
Zhu, AX;Chen, D;He, W;Kanai, M;Voi, M;Chen, LT;Daniele, B;Furuse, J;Kang, YK;Poon, RT;Vogel, A;Chiang, DY |
| 國家衛生研究院 |
2014-07-02 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 國家衛生研究院 |
2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 國家衛生研究院 |
2013-12 |
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
|
Finn, RS;Poon, RTP;Yau, T;Klümpen, HJ;Chen, LT;Kang, YK;Kim, TY;Gomez-Martin, C;Rodriguez-Lope, C;Kunz, T;Paquet, T;Brandt, U;Sellami, D;Bruix, J |
| 國家衛生研究院 |
2013-11 |
Management of gastric cancer in Asia: Resource-stratified guidelines
|
Shen, L;Shan, YS;Hu, HM;Price, TJ;Sirohi, B;Yeh, KH;Yang, YH;Sano, T;Yang, HK;Zhang, X;Park, SR;Fujii, M;Kang, YK;Chen, LT |
| 國家衛生研究院 |
2013-06-21 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
|
Roy, AC;Park, SR;Cunningham, D;Kang, YK;Chao, Y;Chen, LT;Rees, C;Lim, HY;Tabernero, J;Ramos, FJ;Kujundzic, M;Cardic, MB;Yeh, CG;De Gramont, A |
Showing items 21-30 of 30 (3 Page(s) Totally)
<< < 1 2 3
View [10|25|50] records per page
|
